Navigation Links
Regeneron Ranked by Science Magazine as the #2 Employer in the Global Biopharmaceutical Industry
Date:9/15/2011

biotechnology, biopharmaceutical, pharmaceutical, and related industries to determine the driving characteristics of the best employers and to identify the 20 best employers from a universe of about 200 companies.  Respondents to the web-based survey were asked to rate companies based on 23 characteristics, including financial strength, easy adaptation to change, and a research-driven environment.

According to Science, the 2011 global survey results were based on 3,784 responses from North America (80%), Europe (12%), and Asia/Pacific Rim (6%).  A mathematical process was used to assign a unique score to rate each company's employer reputation.

About Regeneron Pharmaceuticals Regeneron is a fully integrated biopharmaceutical company that discovers, develops, manufacturers, and commercializes medicines for the treatment of serious medical conditions. In addition to ARCALYST® (rilonacept) Injection for Subcutaneous Use, which is approved for the treatment of a rare inflammatory condition, Regeneron has completed Phase 3 clinical trials of rilonacept for a new indication and of product candidates EYLEA™ (aflibercept injection; VEGF Trap Eye) in diseases of the eye and ZALTRAP® (aflibercept) (VEGF Trap) in colorectal cancer.  EYLEA is currently under review with U.S. and European regulatory authorities.  Additional therapeutic candidates developed from proprietary Regeneron technologies for creating fully human monoclonal antibodies are in earlier stage development programs in rheumatoid arthritis, pain, cholesterol reduction, allergic and immune conditions, and cancer.  Additional information about Regeneron and recent news releases are available on www.regeneron.com.Contact Information:Michael Aberman, M.D.

Peter DworkinInvestor Relations

Corporate Communications914.345.7799

914.345.7640michael.a
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Regeneron Announces Clinical Presentations at ASRS 2011 Annual Meeting
2. Regeneron Reports Second Quarter 2011 Financial and Operating Results
3. Sanofi and Regeneron Report Positive Phase 2b Trial Results with Sarilumab in Rheumatoid Arthritis
4. Trading in Regeneron Common Stock Halted
5. Regeneron Reports First Quarter 2011 Financial and Operating Results
6. Regeneron Announces Presentation at the Bank of America Merrill Lynch 2011 Health Care Conference
7. Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Second Phase 3 Study in Central Retinal Vein Occlusion
8. Regeneron and Bayer Announce Start of Phase 3 Clinical Program in Diabetic Macular Edema
9. Regeneron Announces Presentation at the 10th Annual Needham Healthcare Conference
10. Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer
11. Regeneron Announces March 2011 Investor Conference Presentations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... June 30, 2015   Millar, Inc. , a ... announced the 2016 retirement of Craig Thummel , ... 12 years of service to the Company. The Company ... senior members of the Executive Management team as his ... Daugherty , currently Director of Sales and Marketing, as ...
(Date:6/30/2015)... NEW YORK , June 30, 2015 /PRNewswire/ ... a late stage pharmaceutical company focused on the ... today announced the closing of its previously announced ... stock. The underwriters also exercised their over-allotment option ... of common stock. The net proceeds ...
(Date:6/30/2015)... June 24, 2015 ... addition of the "Global Array Instruments Market ... The global array instruments market to grow at ... 2014-2019 The global array instruments market can ... microarrays, and others including tissue microarrays and cell ...
Breaking Medicine Technology:Millar, Inc. Announces Leadership Changes 2Millar, Inc. Announces Leadership Changes 3Dipexium Announces Closing of Public Offering of Common Stock 2Dipexium Announces Closing of Public Offering of Common Stock 3Global Array Instruments Market 2015-2019 - Advances in Personalized Medicines with Affymetrix, Agilent Technologies & Illumina Dominating 2
... Roche announced today the opening of a new ... Nutley, N.J. The Roche Center of Excellence produces dosage ... and Phase 1 and 2 clinical studies. The 17,000 ... compounds into medicines for clinical trials. ...
... Sept. 30, 2011 The CyberKnife Coalition ... the CyberKnife Robotic Radiosurgery System® have now been enrolled ... track prostate cancer patients treated with stereotactic ... Radiosurgery (RPCR), tracks clinical and functional outcomes of men ...
Cached Medicine Technology:Roche Opens New Center of Excellence Facility 2First Prostate Cancer Registry for Robotic Radiosurgery Patients Enrolls More than 500 Men 2
(Date:6/30/2015)... ... 2015 , ... Rocky Mountain Oils, a leading non-MLM supplier of premium ... new CEO, Mr. Darold Francis. The changes will help enhance the company’s focus on ... have come to know and respect for over eight years. , “I am thrilled ...
(Date:6/30/2015)... CA (PRWEB) , ... June 30, 2015 , ... ... the community. , Eleven physicians from Allied’s Fullerton division volunteered to help provide ... annual Super Surgery Saturday, March 21, at St. Jude Medical Center. , ...
(Date:6/30/2015)... ... June 30, 2015 , ... MJH Associates ... HRA Healthcare Research & Analytics , a consultative healthcare market research practice ... family of businesses. HRA offers quantitative and qualitative, custom and multi-client primary market ...
(Date:6/30/2015)... , ... June 30, 2015 , ... Red Hot ... in a recent online poll at http://scoutology.com/novaburgerwars and was selected as “Best ... published in August 2015. , Red Hot & Blue President Randy McCann said, “Everyone ...
(Date:6/30/2015)... ... June 30, 2015 , ... An opinion ... that fat transfer procedures had over breast implants when reconstructing breasts after a ... that “look and feel natural,” have increased sensation, and are less likely than ...
Breaking Medicine News(10 mins):Health News:Rocky Mountain Oils Adds New CEO, Announces Relocation of Operations to Orem, Utah 2Health News:Allied Anesthesia Physicians Volunteer to Help Orange County’s Uninsured During Annual Super Surgery Saturday 2Health News:Allied Anesthesia Physicians Volunteer to Help Orange County’s Uninsured During Annual Super Surgery Saturday 3Health News:HRA Healthcare Research & Analytics Welcomes 'Creative Problem Solver' as New Executive Vice President 2Health News:HRA Healthcare Research & Analytics Welcomes 'Creative Problem Solver' as New Executive Vice President 3Health News:Red Hot & Blue BBQ Restaurants Voted "Best Burger" in Virginia and "Best Barbecue" in Texas 2Health News:Red Hot & Blue BBQ Restaurants Voted "Best Burger" in Virginia and "Best Barbecue" in Texas 3Health News:Recent Article Advocating for Breast Reconstruction with Fat Transfers Successfully Outlines the Advantages of Transfer Procedures, Notes Beverly Hills Physicians 2Health News:Recent Article Advocating for Breast Reconstruction with Fat Transfers Successfully Outlines the Advantages of Transfer Procedures, Notes Beverly Hills Physicians 3
... Wake Forest University Baptist Medical Center, US, have found ... children with cancer, and thus limits the side effects ... looked into the chemotherapy given to children suffering from ... type of childhood cancer were administered very limited dosage ...
... may be used to treat the problem of severe ... palsy. ,Children suffering from cerebral palsy and other ... have the control over the salivary reflex. This condition ... from being a constant problem for parents or people ...
... Medical School say that for people whose blood pressure do ... levels. ,In a healthy normal person blood pressure ... late night, or sleep disturbances may elevate the nighttime blood ... fact such higher levels of blood pressure at night may ...
... Researchers have identified a virus that targets and kills a ... virus (VSV) can successfully target and kill glioblastoma, which is ... a form of brain tumor that is resistant to modern ... Medicine had taken nine different DNA and RNA viruses through ...
... had invented a therapeutic vaccine Cytos002-NicQb that can cure//smokers ... quit smoking. ,Swiss researchers for the study, in ... had said that the vaccine for nicotine dependence had ... trials successfully. The first phase of the study had ...
... by Harvard School of Public Health suggests that obesity ... if already existing. ,Obesity had been conclusively associated ... and certain forms of cancer. This is for the ... asthma. ,In obese people lungs are under-expanded and ...
Cached Medicine News:
... scaleable device that works with ... plasma or buffy coat. The ... must be prepared independently using ... volume and concentration factor can ...
Avitene Microfibrillar Collagen (MCH) is used in surgical procedures as an adjunct to hemostasis when control of bleeding by ligature or conventional procedures is ineffective or impractical....
The Ultrafoam Collagen Sponge is indicated in all surgical procedures as an adjunct to hemostasis when control by ligature or conventional procedures are ineffective or impractical....
Exclusive oxidized regenerated cellulose technology. The only oxidized regenerated cellulose hemostat line, surgicel absorbable hemostat delivers a unique combination of effectiveness, absorbability,...
Medicine Products: